Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Project:
Instituto de Salud Carlos III PI21/00791
,
Ministerio de Economía y Competitividad PI14/01126
,
Instituto de Salud Carlos III PI17/01019
,
Instituto de Salud Carlos III PI20/01473
,
Ministerio de Economía y Competitividad PI13/01532
,
Ministerio de Economía y Competitividad PI16/01825
,
Instituto de Salud Carlos III PI18/00335
,
Instituto de Salud Carlos III PI22/00785
,
Instituto de Salud Carlos III PI19/00882
,
Instituto de Salud Carlos III PI18/00435
,
Instituto de Salud Carlos III PI22/00611
,
Instituto de Salud Carlos III PI17/01896
,
Instituto de Salud Carlos III AC19/00103
,
Generalitat de Catalunya 2017/SGR-00547
,
Generalitat de Catalunya SLT006/17/125
,
Generalitat de Catalunya SLT006/17/119
,
Generalitat de Catalunya SLT002/16/408
,
"la Caixa" Foundation 20141210
,
"la Caixa" Foundation 044412
,
"la Caixa" Foundation 20142610
,
Instituto de Salud Carlos III PI23/01786